Assertio Holdings Inc (ASRT)
1.02
-0.01
(-0.97%)
USD |
NASDAQ |
May 06, 10:48
Assertio Holdings 1 Year Total Returns (Daily): -82.66% for May 3, 2024
1 Year Total Returns (Daily) Chart
Historical 1 Year Total Returns (Daily) Data
Date | Value |
---|---|
May 03, 2024 | -82.66% |
May 02, 2024 | -82.56% |
May 01, 2024 | -83.98% |
April 30, 2024 | -83.94% |
April 29, 2024 | -84.61% |
April 26, 2024 | -83.44% |
April 25, 2024 | -85.38% |
April 24, 2024 | -86.48% |
April 23, 2024 | -85.26% |
April 22, 2024 | -85.98% |
April 19, 2024 | -87.20% |
April 18, 2024 | -87.58% |
April 17, 2024 | -87.44% |
April 16, 2024 | -87.35% |
April 15, 2024 | -87.05% |
April 12, 2024 | -85.36% |
April 11, 2024 | -84.87% |
April 10, 2024 | -84.86% |
April 09, 2024 | -85.20% |
April 08, 2024 | -84.95% |
April 05, 2024 | -84.23% |
April 04, 2024 | -84.48% |
April 03, 2024 | -84.87% |
April 02, 2024 | -85.41% |
April 01, 2024 | -85.31% |
Date | Value |
---|---|
March 28, 2024 | -84.68% |
March 27, 2024 | -83.50% |
March 26, 2024 | -82.59% |
March 25, 2024 | -82.25% |
March 22, 2024 | -82.13% |
March 21, 2024 | -82.29% |
March 20, 2024 | -82.01% |
March 19, 2024 | -82.68% |
March 18, 2024 | -82.16% |
March 15, 2024 | -80.28% |
March 14, 2024 | -81.59% |
March 13, 2024 | -78.24% |
March 12, 2024 | -82.40% |
March 11, 2024 | -83.72% |
March 08, 2024 | -84.70% |
March 07, 2024 | -85.22% |
March 06, 2024 | -85.43% |
March 05, 2024 | -85.71% |
March 04, 2024 | -85.79% |
March 01, 2024 | -85.22% |
February 29, 2024 | -84.02% |
February 28, 2024 | -84.68% |
February 27, 2024 | -84.09% |
February 26, 2024 | -83.92% |
February 23, 2024 | -83.79% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
-88.23%
Minimum
Apr 03 2020
305.0%
Maximum
Aug 22 2022
-8.09%
Average
-44.59%
Median
Mar 01 2022
1 Year Total Returns (Daily) Benchmarks
Ocular Therapeutix Inc | -0.32% |
Cormedix Inc | 15.87% |
Verastem Inc | 106.4% |
Puma Biotechnology Inc | 84.79% |
CytomX Therapeutics Inc | 168.5% |